Finerenone (Kerendia)
Defines medical necessity criteria, initial and continuation approval, dosing limits, exclusions, and appendix therapeutic alternatives for finerenone (Kerendia) across Commercial, HIM, and Medicaid lines of business.
4Q 2025 annual review: added new heart failure indication and accompanying 40 mg dosage strength; for CKD, added criterion requiring serum potassium ≤ 5.0 mEq/L per PI.
4Q 2024 annual review: removed upper eGFR limit of 75 mL/min/1.73 m2 and added concurrent SGLT2 inhibitor use as an option to failure of an SGLT2 inhibitor.
4Q 2023 annual review: no significant changes; references reviewed and updated.